Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
NCT ID: NCT00547586
Last Updated: 2020-08-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
122 participants
INTERVENTIONAL
2007-10-31
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
NCT00605644
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
NCT00529087
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01323790
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
NCT01207427
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01309841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
placebo
placebo
150 mg
N-methylnaltrexone bromide (MOA-728)
Oral
300 mg
N-methylnaltrexone bromide (MOA-728)
Oral
450 mg
N-methylnaltrexone bromide (MOA-728)
Oral
600 mg
N-methylnaltrexone bromide (MOA-728)
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-methylnaltrexone bromide (MOA-728)
Oral
placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Taking oral, transdermal, intravenous, or subcutaneous opioids.
* Willingness to discontinue all pre-study laxative therapy and use only study permitted rescue laxatives.
Exclusion Criteria
* Other GI disorders known to affect bowel transit.
* Women who are pregnant, breast-feeding, or plan to become pregnant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Progenics Pharmaceuticals, Inc.
INDUSTRY
Bausch Health Americas, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mobile, Alabama, United States
Litchfield Park, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Hot Springs, Arkansas, United States
Hot Springs, Arkansas, United States
Garden Grove, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Murrieta, California, United States
San Diego, California, United States
Chiefland, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Largo, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Ormond Beach, Florida, United States
Spring Hill, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Sunset, Louisiana, United States
Elkridge, Maryland, United States
Brockton, Massachusetts, United States
Cadillac, Michigan, United States
Traverse City, Michigan, United States
Biloxi, Mississippi, United States
Ocean Springs, Mississippi, United States
Las Vegas, Nevada, United States
Albuquerque, New Mexico, United States
Charlotte, North Carolina, United States
Winston-Salem, North Carolina, United States
Dayton, Ohio, United States
Toledo, Ohio, United States
Medford, Oregon, United States
Chattanooga, Tennessee, United States
Beaumont, Texas, United States
Colleyville, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Alexandria, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3200A3-2201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.